Lisa Walter
Stock Analyst at RBC Capital
(2.80)
# 1,938
Out of 5,055 analysts
11
Total ratings
87.5%
Success rate
15.62%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Lisa Walter
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MGTX MeiraGTx Holdings | Maintains: Outperform | $12 → $16 | $7.88 | +103.05% | 1 | Nov 14, 2025 | |
| FDMT 4D Molecular Therapeutics | Maintains: Outperform | $26 → $32 | $10.95 | +192.24% | 2 | Nov 11, 2025 | |
| VRDN Viridian Therapeutics | Maintains: Outperform | $41 → $45 | $29.00 | +55.17% | 2 | Nov 6, 2025 | |
| EYPT EyePoint Pharmaceuticals | Maintains: Outperform | $28 → $39 | $13.14 | +196.92% | 2 | Nov 6, 2025 | |
| UTHR United Therapeutics | Maintains: Outperform | $569 → $587 | $471.92 | +24.39% | 2 | Oct 30, 2025 | |
| ADVM Adverum Biotechnologies | Maintains: Sector Perform | $3 → $4 | $4.27 | -6.32% | 1 | Oct 28, 2025 | |
| APLS Apellis Pharmaceuticals | Maintains: Sector Perform | $17 → $19 | $20.10 | -5.47% | 1 | Aug 1, 2025 |
MeiraGTx Holdings
Nov 14, 2025
Maintains: Outperform
Price Target: $12 → $16
Current: $7.88
Upside: +103.05%
4D Molecular Therapeutics
Nov 11, 2025
Maintains: Outperform
Price Target: $26 → $32
Current: $10.95
Upside: +192.24%
Viridian Therapeutics
Nov 6, 2025
Maintains: Outperform
Price Target: $41 → $45
Current: $29.00
Upside: +55.17%
EyePoint Pharmaceuticals
Nov 6, 2025
Maintains: Outperform
Price Target: $28 → $39
Current: $13.14
Upside: +196.92%
United Therapeutics
Oct 30, 2025
Maintains: Outperform
Price Target: $569 → $587
Current: $471.92
Upside: +24.39%
Adverum Biotechnologies
Oct 28, 2025
Maintains: Sector Perform
Price Target: $3 → $4
Current: $4.27
Upside: -6.32%
Apellis Pharmaceuticals
Aug 1, 2025
Maintains: Sector Perform
Price Target: $17 → $19
Current: $20.10
Upside: -5.47%